Pharmaceutical companies are well aware there is a trend toward shifting the financial burden to the patient that can be seen in many markets. Traditionally, patients have had the payer role in the emerging private pay markets, such as China and India. The US is also an obvious example of where co-payments are the norm. Other countries, traditionally thought of as fully reimbursed, are increasingly passing this burden over to patients. Spain, for example, levies a 40-60% co-pay depending on....